CD276 and melanoma: Metastatic melanoma cells with knockdown expression of B7-H3 showed modest decrease in proliferation and glycolytic capacity and were more sensitive to dacarbazine chemotherapy and small-molecule inhibitors (e.g., MEK and AKT/mTOR inhibitors) [193].